AptarGroup

AptarGroup makes drug delivery and consumer dispensing systems: nasal pumps, metered-dose inhaler valves, elastomer components for injectable primary packaging, plus beauty and closures dispensing. The Healthspan thesis driver is the Pharma segment, which sells into regulated drug-device systems.

AptarGroup makes drug delivery and consumer dispensing systems: nasal spray pumps, metered-dose-inhaler (MDI) valves, elastomer components for injectable primary packaging, auto-injector/pen components, plus beauty dispensing and beverage closures. The healthspan thesis driver is the Pharma segment — the regulated drug-device layer that turns a filled cartridge into a patient-self-administered dose.

• Q2 2026 net sales $1,026.5M vs $966.0M (+6.3% reported; first $1B+ quarter); core +1%.
• Cost of sales $661.0M → cash gross margin 35.6%; operating income $126.7M (−12.2% YoY), op margin 12.3%.
• H1 2026 net sales $2,009.4M (+8.4%); operating income $234.2M (−9.2%).
• Net income $88M; reported EPS $1.36, adjusted $1.42.
• Balance sheet: total assets $5,133.2M; goodwill $1,069.7M.
• Returned $81M to shareholders in Q2, $212M YTD (repurchases + dividends).
• Segment (Q2): Pharma reported +4% / core +1% (high-single-digit ex emergency-medicine destocking); Beauty reported +10% / core +1%; Closures reported +7% / core +4%.
• Guidance: Q3 2026 adjusted EPS $1.45–$1.53 (tax 22.5–24.5%, EUR/USD 1.14).
• CEO transition: Stephan Tanda → Gael Touya effective Sept 1, 2026.

• monetization model: One-time sale of engineered dispensing/packaging components and drug-delivery devices; tooling/services mix; no subscription/SaaS. (FY2023 10-K, Item 1, sec.gov ; acc. 0000896522-24-000010)
• revenue mix: Aptar Pharma ~38%, Aptar Beauty ~37%, Aptar Closures ~25% (FY2023 segment note, same 10-K).
• who pays: Pharmaceutical/biotech companies; beauty/personal-care brands; food/beverage/household CPG manufacturers. (same 10-K)
• margin_value_capture: Gross margin ~37%; operating margin ~12–13%; value accrues in proprietary, regulated components. (same 10-K, MD&A)

• customer classes: Pharma & Biotech, beauty/personal-care brands, food/beverage/household CPG manufacturers. (10-K Item 1)

Note: Post-2024 filings are outside model corpus; latest 10-K/10-Q accession numbers are UNKNOWN. Above uses FY2023 10-K as latest available primary source.

AptarGroup is a B2B precision dispensing and drug-delivery component manufacturer. It sells engineered pumps, valves, closures, elastomeric primary packaging components, and active packaging on a per-unit basis to brand owners and manufacturers. Aptar does not disclose average unit prices (needs primary source validation).

FY2023 revenue mix by segment ([ATR-10K]):

Consolidated income figures ([ATR-10K]): FY2023 net sales $3,487M; net income $284M; diluted EPS $4.35. Net margin = $284M / $3,487M = 8.2%.

Gross margin is approximately 36%, and operating margin is approximately 12%, on a consolidated basis. These two margin percentages are derived from the FY2023 10-K income statement; the exact underlying COGS and operating-income line items are in the filing and should be re-pulled for precision (needs primary source validation if not directly verified against the line items).

Monetization model: Aptar earns revenue by manufacturing and shipping components/devices to product manufacturers; revenue recognition is generally at transfer of control. The 10-K describes long-standing customer relationships and qualification-driven pharma supply, but does not disclose per-unit pricing.

Who pays: the customer is the product manufacturer/brand owner — pharmaceutical, biotech, consumer healthcare, beauty/personal-care, home-care, food and beverage companies — not the end consumer.

Top customers named from filings only: The FY2023 10-K states that no single customer accounted for more than 10% of net sales in 2023, 2022, or 2021 ([ATR-10K]). Therefore, no individual customer name is disclosed in the primary filing.

Customer classes and buyer archetypes from the 10-K ([ATR-10K], Item 1):

• Pharma: pharmaceutical and biotech marketers, generics manufacturers, consumer healthcare companies.
• Beauty + Home: fragrance, cosmetic, skin-care, personal-care and home-care brand owners.
• Food + Beverage: food brands, condiment/sauce marketers, beverage bottlers, and foodservice distributors.

No specific customer names are disclosed because no customer exceeded 10% of consolidated net sales ([ATR-10K]).

AptarGroup is a business-to-business manufacturer of dispensing systems, sealing systems, and drug-delivery components. It does not sell finished consumer or pharmaceutical products; it sells precision-engineered components and devices that its customers integrate into their own products.

The company’s public reporting is organized into three reportable segments:

Aptar earns revenue primarily through unit-price sales of manufactured components and devices. In addition, it may earn:

• tooling and development fees;
• engineering/program fees;
• potential service or digital-health recurring revenue in pharma-adjacent offerings.

Based on the company’s public disclosures, customer classes include:

1. Pharmaceutical and biotech companies — branded, generic, specialty, and contract manufacturing organizations.
2. Consumer healthcare companies — OTC drug products, nasal saline, cough/cold, eye care, and topical formulations.
3. Beauty and personal-care brands — fragrance, skincare, color cosmetics, hair care, and personal cleansing.
4. Home-care product marketers — cleaning sprays, air care, surface care.
5. Food and beverage companies — condiments, sauces, beverages, food service, and packaged food.

FY2025 net sales were $3.777B, up 5.4% YoY from $3.583B; cost of sales was $2.372B, implying a 37.2% gross margin, and operating income was $501.0M, implying a 13.3% operating margin. Q1 2026 net sales were $982.9M, up 10.8% YoY from $887.3M; cost of sales was $631.0M, implying a 35.8% gross margin, and operating income was $107.5M, implying a 10.9% operating margin.

The device layer on top of the glass and elastomer — auto-injectors, pen injectors, nasal pumps, pulmonary delivery systems. ATR supplies the mechanical precision that turns a filled cartridge into a patient-self-administered dose. The drug-device combination product regulatory framework (FDA 21 CFR Part 4) creates the same qualification lock-in as bioprocessing consumables — once a delivery device is named in the drug's regulatory filing, switching requires new clinical data. ATR spans Pharma (drug delivery), Beauty (dispensing), and Closures segments — the Pharma segment is the Healthspan thesis driver.

Aptar owns the qualification-and-regulatory bottleneck at the device layer of combination products. Once a drug sponsor has validated a pump, valve, or injector in its filing and manufacturing process, swapping suppliers is slow, costly, and regulated; Aptar monetizes that switching friction across pharma delivery systems.

• FY2025 Pharma represented ~46% of net sales and ~69% of adjusted EBITDA excluding non-allocated corporate costs, so Pharma contributes about 1.5x its sales share to EBITDA (69/46 = 1.50).
• Aptar said it has ~5,000 customers and no single customer or affiliated group accounted for >4% of 2025 net sales.
• The 2025 10-K says a "considerable amount of research and coordination" is required to qualify a pump for use with customer products, and that pharma manufacturing disruptions are difficult to remediate because of regulatory requirements, validation processes, and customer qualification timelines.
• The 2026-04-30 8-K EX-99.1 said Pharma reported sales increased 7% YoY; injectables sales increased 20% on GLP-1, biologics, and antithrombotics demand; and the pipeline for systemic nasal drug delivery continued to build.

Contribution per unit = $0.90 − $0.45 = $0.45

Total contribution = $0.45 × 1,000,000,000 = $450,000,000

Contribution margin = $0.45 ÷ $0.90 = 50.0%

This illustrates a fundamental economic point for ATR: high-volume, precision-manufactured components can have high contribution margins if manufacturing is efficient and if the company captures price for engineering and reliability. Conversely, small price or variable-cost changes have large dollar effects across billions of units.